📢 We are excited to announce that MyoPax has been selected to join the Bayer Co.Lab network.
On November 28, 2024, at the opening of the new Berlin site for this inspiring initiative, we proudly announced our new home and took the opportunity to underscore our mission: sustainably addressing severe muscle weakness through cutting-edge therapeutic approaches. Engaging with the event’s forward-focused community was an absolute highlight.
It was fantastic to see Kai Wegner, the governing mayor of Berlin / Senatskanzlei Berlin, in attendance, demonstrating strong support for the city’s biotech scene and emphasizing its crucial role in driving future innovation.
MyoPax is ready 🚀
We are honored to be part of the Co.Lab network, marking a next part of our journey:
🔬 State-of-the-art infrastructure and access to profound expertise
🌍 International collaboration: Hashtag#Berlin Hashtag#Cambridge Hashtag#Kobe Hashtag#Shanghai
🤝 Harnessing the collective strength of startups
We are especially grateful to Ruth Shah and her Bayer Co.lab Berlin team for making this possible and fostering such a vibrant, uplifting atmosphere. A special thank you goes to Stefan Oelrich/Head of the Pharmaceuticals Division Bayer, Christian Rommel/Head of Research and Development, Friedemann Janus/Senior Vice President and Head of Business Development & Licensing, Juergen Eckhardt/EVP and Head of Leaps and the Bayer team for this opportunity and championing visibility and providing encouragement to our biotech start-up community.
